Brief: Can Fite Biopharma Reports New Data On Namodenoson's Anti-Obesity Mechanism Of Action

Can Fite Biopharma

20/12/2023 12:12

Dec 20 (Reuters) - Can Fite Biopharma Ltd  CANF.TA :
    * CAN FITE BIOPHARMA LTD - NEW DATA ON NAMODENOSON'S
ANTI-OBESITY
MECHANISM OF ACTION
    * CAN FITE BIOPHARMA LTD - TREATMENT OF FAT CELLS WITH
NAMODENOSON
LEADS TO MODULATION OF PROTEINS THAT INCREASE ADIPONECTIN LEVEL
    * CAN FITE BIOPHARMA LTD - NAMODENOSON REDUCED BODY WEIGHT
IN AN
EXPERIMENTAL ANIMAL MODEL OF OBESITY INDUCED BY A HIGH FAT DIET
    * CAN FITE BIOPHARMA LTD - IN A PHASE IIA NASH STUDY, IN
PATIENTS
TREATED WITH NAMODENOSON, A 2.1% WEIGHT LOSS WAS OBSERVED AFTER
3 MONTHS OF TREATMENT

Source text for Eikon:  ID:nBw74hKJqa 
Further company coverage:  CANF.TA 

 ((Reuters.Briefs@thomsonreuters.com;))